Skip to main content

Drug Safety

    RT @drdavidliew: Was ORAL Surveillance really a surprise?
    Let's look post-hoc at all the other tofacitinib RCTs (ph 1-3b
    1 year 11 months ago
    Was ORAL Surveillance really a surprise? Let's look post-hoc at all the other tofacitinib RCTs (ph 1-3b/4 +LTE) Cardiovascular risk-enriched pts were always in the same MACE ballpark with tofa ORAL Surveillance was worse, but clues were always there OP0264 #EULAR2022 @RheumNow https://t.co/rB5SwVX2oc
    RT @RichardPAConway: Montastruc et al. VigiBase study of CV and VTE events in JAKi vs TNFi. >270000 events. DECREASE
    1 year 11 months ago
    Montastruc et al. VigiBase study of CV and VTE events in JAKi vs TNFi. >270000 events. DECREASE in MACE ROR=0.87 [95%CI 0.80-0.95]. INCREASE in DVT: ROR=3.99 [3.15-5.04], PE: ROR=3.47 [2.90-4.13] @RheumNow #EULAR2022 OP0268 https://t.co/lUin7ciXWt https://t.co/Gr4Kvd8F7R
    RT @drdavidliew: MACE in JAKi vs TNFi: did spontaneous reporting pharmacovigilance pick it?

    Vigibase: MACE (really MI)
    1 year 11 months ago
    MACE in JAKi vs TNFi: did spontaneous reporting pharmacovigilance pick it? Vigibase: MACE (really MI) & VTE signals there before the scare Always chance regulatory warnings cause stimulated reporting but signal here was clear before RCT-driven alerts OP0268 #EULAR2022 @RheumNow https://t.co/hTJD1gMgyy
    Video: Further Considerations of the ORAL Surveillance Study

    Further Considerations of ORAL Surveillance Study - this w
    1 year 11 months ago
    Video: Further Considerations of the ORAL Surveillance Study Further Considerations of ORAL Surveillance Study - this week there are new analyses and sub-analyses that further explain findings and who this data applies to. #EULAR2022 https://t.co/a2XKthtMbs https://t.co/kYNS1AesHT
    A full day at EULAR with oral and poster presentations of abstracts in the morning and a plethora of scientific (review) sessions in the afternoon.  The latter covering topics like sarcoidosis,…
    EULAR Congress 2022 highlighted several posters on pregnancy, an important subject as most rheumatic diseases afflicts women during their childbearing years. I wanted to share with you the ones…
    Translating targeted therapy from bench to bedside has been more problematic in systemic lupus erythematosus (SLE) than other autoimmune diseases, with many theoretically well-founded agents…
    Belimumab Use in Pregnancy